Open-Label, Non-Randomized, Non-Controlled, Multicenter Phase II Study Investigating Cetuximab in Combination With Concomitant-Boost Radiotherapy as First-Line Treatment for Japanese Patients With Newly Diagnosed Locally Advanced SCCHN.

Trial Profile

Open-Label, Non-Randomized, Non-Controlled, Multicenter Phase II Study Investigating Cetuximab in Combination With Concomitant-Boost Radiotherapy as First-Line Treatment for Japanese Patients With Newly Diagnosed Locally Advanced SCCHN.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 May 2014

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Sponsors Merck KGaA
  • Most Recent Events

    • 17 Aug 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 17 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top